Deutsche Bank Ag\ Shattuck Labs, Inc. Transaction History

Deutsche Bank Ag\

$240 Billion
Q3 2024

A detailed history of Deutsche Bank Ag\ transactions in Shattuck Labs, Inc. stock. As of the latest transaction made, Deutsche Bank Ag\ holds 20,274 shares of STTK stock, worth $23,315. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,274

Holding current value

$23,315

% of portfolio

0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	BUY	$3.0 - $4.85 $60,822 - $98,328	20,274 New	20,274 $70,000
Q2 2022 Aug 11, 2022	SELL	$2.7 - $4.59 $41,652 - $70,809	-15,427 Closed	0 $0
Q1 2022 May 13, 2022	SELL	$4.22 - $8.89 $7,258 - $15,290	-1,720 Reduced 10.03%	15,427 $66,000
Q4 2021 Feb 11, 2022	BUY	$8.36 - $21.08 $7,223 - $18,213	864 Added 5.31%	17,147 $146,000
Q3 2021 Nov 04, 2021	SELL	$17.57 - $28.95 $8,662 - $14,272	-493 Reduced 2.94%	16,283 $332,000
Q2 2021 Aug 11, 2021	BUY	$24.14 - $37.68 $194,013 - $302,834	8,037 Added 91.97%	16,776 $486,000
Q1 2021 May 13, 2021	SELL	$27.92 - $52.5 $22,112 - $41,580	-792 Reduced 8.31%	8,739 $255,000
Q4 2020 Feb 16, 2021	BUY	$19.0 - $57.61 $181,089 - $549,080	9,531 New	9,531 $500,000

Others Institutions Holding STTK

# of Institutions

Shares Held

28.8M

Call Options Held

300

Put Options Held

1.2K

Prosight Management, LP Dallas, TX

5.68M
Shares

$6.53 Million
5.32% of portfolio
Redmile Group, LLC San Francisco, CA

5.62M
Shares

$6.46 Million
1.28% of portfolio
Adage Capital Partners Gp, L.L.C. Boston, MA

2.9M
Shares

$3.33 Million
0.02% of portfolio
Black Rock Inc. New York, NY

2.47M
Shares

$2.85 Million
0.0% of portfolio
Vanguard Group Inc Valley Forge, PA

2.4M
Shares

$2.76 Million
0.0% of portfolio

View Full List

About Shattuck Labs, Inc.

Ticker STTK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 42,382,000
Market Cap $48.7M
Description
Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is ...

More about STTK

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Deutsche Bank Ag\, based on Form 13F filings with the SEC.

News

Stay updated on Deutsche Bank Ag\ with notifications on news.

Account